Skip to main content
SpringerLink
Log in

Serum paraoxonase 1 activity is decreased in thyroid dysfunction

  • Original Article
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Changes in serum lipid and lipoprotein concentrations occur frequently in disorders of thyroid function. LDL-cholesterol (LDL-C) oxidation susceptibility is higher in these patients than in normal population. This study aims at assessing lipids, lipoproteins, apolipoproteins and serum paraoxonase 1 (PON1) activity in patients with thyroid dysfunction. Ninety-nine patients with thyroid dysfunction, (49 hypothyroid and 50 hyperthyroid) were compared with 2 separately age- and sexmatched control groups. A fasting blood sample was obtained and serum total cholesterol, triglycerides, apolipoproteins A-I and B, and PON1 activity were measured. In hyperthyroid patients, significantly lower PON1 activity (45±23 vs 67±37 IU/ml, p<0.001), triglycerides (112±53 vs 166±130 mg/dl, p<0.05), apolipoprotein A-I (137±26 vs 154±21 mg/dl, p<0.001) and apolipoprotein B (75±18 vs 86±25 mg/dl, p<0.05) were found. Hypothyroid patients had lower PON1 activity (46±21 vs 64±32 IU/ml, p<0.005) compared with controls, and higher total cholesterol (224±69 vs 185±41 mg/dl, p<0.001), LDL-C (133±59 vs 93±36 mg/dl, p<0.001), and apolipoprotein B (107±37 vs 84±23 mg/dl, p<0.001). The results show significant changes of lipid levels in thyroid dysfunction. In addition, a significant reduction in PON1 activity was observed in both hyper- and hypothyroid patients. Increased LDL-C oxidation in thyroid dysfunction observed in other studies, at least to some extent, can be attributed to reduced PON1 activity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Aviram M., Lubushitzky R., Brook J.G. Lipid and lipoprotein pattern in thyroid dysfunction and the effect of therapy. Clin. Biochem. 1982. 15: 62–66.

    Article  PubMed  CAS  Google Scholar 

  2. Costantini F., Pierdomenico S.D., De Cesare D., et al. Effect of thyroid function on LDL oxidation. Arterioscler. Thromb. Vasc. Biol. 1998, 18: 732–737.

    Article  PubMed  CAS  Google Scholar 

  3. Sundaram V., Hanna A.N., Konerul L., Newman H.A., Falko J.M. Both hypothyroidism and hyperthyroidism enhance low-density lipoprotein oxidation. J. Clin. Endocrinol. Metab. 1997, 82: 491–494.

    Google Scholar 

  4. DeGroot L.J. Thyroid and the heart. Mayo Clin. Proc. 1972, 47: 864–871.

    PubMed  CAS  Google Scholar 

  5. Agdeppa D., Macoron C., Mallik T., Schnuda N.D. Plasma high density lipoprotein cholesterol in thyroid disease. J. Clin. Endocrinol. Metab. 1979, 49: 726–729.

    Article  PubMed  CAS  Google Scholar 

  6. Tan K.C., Shiu S.W., Kung A.W. Effect of thyroid dysfunction on high-density lipoprotien subfraction metabolism: roles of hepatic lipase and cholesterol ester transfer protein. J. Clin. Endocrinol. Metab. 1998, 83: 2921–2924.

    PubMed  CAS  Google Scholar 

  7. Valdemarsson S., Hansson P., Hedner P., Nilsson-Ehle P. Relations between thyroid function, hepatic and lipoprotein lipase activities and plasma lipoprotein concentrations. Acta Endocrinol. (Copenh.) 1983, 104: 50–56.

    CAS  Google Scholar 

  8. Hargrove G.M., Junco A., Wong N.C. Hormonal regulation of apolipoprotein A-I. J. Mol. Endocrinol. 1999, 22: 103–111.

    Article  PubMed  CAS  Google Scholar 

  9. Kutty K.M., Bryant D.G., Farid N.R. Serum lipid in hypothyroidism — a reevaluation. J. Clin. Endocrinol. Metab. 1978, 46: 55–60.

    Article  PubMed  CAS  Google Scholar 

  10. O’Brien T., Katz K., Hodge D., Nguyen T.T., Kottke B.A., Hay I.D. The effect of the treatment of hypothyroidism and hyperthyroidism on plasma lipids and apolipoproteins AI, AII and E. Clin. Endocrinol. (Oxf.) 1997, 73: 837–841.

    Google Scholar 

  11. Pazos F., Alvarez J.J., Rubies-Prat J., Varela C., Lasuncion M.A. Long-term thyroid replacement therapy and levels of lipoprotein(a) and other lipoproteins. J. Clin. Endocrinol. Metab. 1995, 80: 562–566.

    PubMed  CAS  Google Scholar 

  12. Kung A.W., Pang R.W., Lauder I., Lam K.S., Janus E.D. Changes in serum lipoprotein(a) and lipids during treatment of hyperthyroidism. Clin. Chem. 1995, 41: 226–231.

    PubMed  CAS  Google Scholar 

  13. Hansson P., Valdemarsson S., Nilsson-Ehle P. Experimental hyperthyroidism in man: effects on plasma lipoproteins, lipoprotein lipase and hepatic lipase. Horm. Metab. Res. 1983, 15: 449–452.

    Article  PubMed  CAS  Google Scholar 

  14. Brun L.D., Gagne C., Coulombe P., Lupien P.J., Dussault J.H., Moorjani S. Effects of dextrothyroxine on the pituitarythyroid axis in hypercholesterolemic children and goitrous adults. J. Clin. Endocrinol. Metab. 1980, 51: 1306–1310.

    Article  PubMed  CAS  Google Scholar 

  15. Tan K.C., Shiu S.W., Kung A.W. Plasma cholesterol ester transfer protein activity in hyper- and hypothyroidism. J. Clin. Endocrinol. Metab. 1998, 83: 140–143.

    PubMed  CAS  Google Scholar 

  16. Ozata M., Yildirimkaya M., Yilmaz K., et al. The effects of thyroid status on serum apolipoptotein A-I containing lipoptotein particles. Horm. Metab. Res. 1998, 30: 217–221.

    Article  PubMed  CAS  Google Scholar 

  17. Dullaart R.P., van Doormaal J.J., Hoogenberg K., Sluiter W.J. Triiodothyronine rapidly lowers plasma lipoprotein( a) in hypothyroid subjects. Neth. J. Med. 1995, 46: 179–184.

    Google Scholar 

  18. Friis T., Pedersen L.R. Serum lipids in hyper- and hypothyroidism before and after treatment. Clin. Chim. Acta 1987, 162: 155–163.

    Article  PubMed  CAS  Google Scholar 

  19. Tsimihodimos V., Bairaktari E., Tzallas C., Miltiadus G., Liberopoulos E., Elisaf M. The incidence of thyroid function abnormalities in patients attending an outpatient lipid clinic. Thyroid 1999, 9: 365–368.

    Article  PubMed  CAS  Google Scholar 

  20. Packard C.J., Shepherd J. Physiology of lipoprotein transport system: an overview of lipoprotein metabolism. In: Betteridge D.J., Illingworth D.R., Shepherd J. (Eds.), Lipoproteins in Health and Disease. Arnold, London, 1995, pp. 17–51.

    Google Scholar 

  21. Navab M., Berliner J.A., Watson A.D., Hama S.Y., Territo M.C., Lusis A.J. The Yin and Yang of oxidation in the development of the fatty streak. Arterioscler. Thromb. Vasc. Biol. 1996, 16: 831–842.

    Article  PubMed  CAS  Google Scholar 

  22. Navab M., Hama S.Y., Hough G.P., et al. High-density associated enzymes: metabolism of apolipoptotein A-I. J. Lipid. Res. 1991, 32: 395–405.

    Google Scholar 

  23. Abbott C.A., Mackness M.I., Kumar S., Boulton A.J., Durrington P.N. Serum paraoxonase activity, concentratrion, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler. Thromb. Vasc. Biol. 1995, 15: 1812–1818.

    Article  PubMed  CAS  Google Scholar 

  24. Azizi F., Rahmani M., Emami H., Majid M. Tehran Lipid and Glucose Stady: Rationale and Design. CVD Prevention 2000, 3: 242–243.

    Google Scholar 

  25. WHO, UNICEF, ICCIDD. Assessment of Iodine Deficiency Disorders and Monitoring Their Elimination: A guide for programme managers. 2nd ed. World Health Organization, Geneva, WHO/NHD/01.1, 2001.

    Google Scholar 

  26. Eckerson H.W., Wyte C.M., La Du B.N. The human serum paraoxonase/arylesterase polymorphism. Am. J. Hum. Genet. 1983, 35: 1126–1138.

    PubMed Central  PubMed  CAS  Google Scholar 

  27. Valdemarsson S., Hedner P., Nilsson-Ehle P. Reversal of decreased hepatic lipase and lipoprotein lipase activities after treatment of hypothyroidism. Eur. J. Clin. Invest. 1982, 12: 423–428.

    Article  PubMed  CAS  Google Scholar 

  28. Althaus B.U., Staub J.J., Ryff-DeLeche A., Oberhansli A., Stahelin H.B. LDL/HDL changes in subclinical hypothyroidism: possible risk factors for coronary heart disease. Clin. Endocrinol. (Oxf.) 1988, 28: 157–163.

    Article  CAS  Google Scholar 

  29. Abrams J.J., Grundy S.M. Cholesterol metabolism in hypothyroidism and hyperthyroidism in man. J. Lipid. Res. 1981, 22: 323–338.

    PubMed  CAS  Google Scholar 

  30. Series J.J., Biggart E.M., O’Reilly D.S., Packard C.J., Shepherd J. Thyroid dysfunction and hypercholesterolaemia in the general population of Glasgow, Scotland. Clin. Chim. Acta 1988, 172: 217–221.

    Article  PubMed  CAS  Google Scholar 

  31. Wilcox H.G., Frank R.A., Heimberg M. Effects of thyroid status and fasting on hepatic metabolism of apolipoprotein A-I. J. Lipid Res. 1991, 32: 395–405.

    PubMed  CAS  Google Scholar 

  32. Thompson G.R., Soutar A.K., Spengel F.A., Jadhav A., Gavigan S.J., Myant N.B. Defects of receptor-mediated low-density lipoptotein catabolism in homozygous familial hypercholesterolemia and hypothyroidism in vivo. Proc. Natl. Acad. Sci. USA 1981, 78: 2591–2595.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  33. Tall A.R. Plasma cholesteryl ester transfers protein. J. Lipid Res. 1993, 34: 1255–1274.

    PubMed  CAS  Google Scholar 

  34. Ritter M.C., Kannan C.R., Bagdade J.D. The effects of hypothyroidism and replacement therapy on cholesteryl ester transfer. J. Clin. Endocrinol. Metab. 1996, 81: 797–800.

    PubMed  CAS  Google Scholar 

  35. Arem R., Patsch W. Lipoprotein and apolipoprotein levels in subclinical hypothyroidism. Effect of levothyroxine therapy. Arch. Intern. Med. 1990, 150: 2097–2100.

    Article  PubMed  CAS  Google Scholar 

  36. Becerra A., Bellido D., Luengo A., Piedrola G., De luis D.A. Lipoprotein(a) and other lipoproteins in hypothyroid patients before and after thyroid replacement therapy. Clin. Nutr. 1999, 18: 319–322.

    Article  PubMed  CAS  Google Scholar 

  37. Diekman M.J., Anghelescu N., Endert E., Bakker O., Wiersinga W.M. Changes in plasma low-density lipoprotein (LDL) and high-density lipoprotein cholesterol in hypo and hyperthyroid patients are related to changes in free thyroxine, not to polymorphisms in LDL receptor of cholesterol ester transfer protein genes. J. Clin. Endocrinol. Metab. 2000, 85: 1857–1862.

    Article  PubMed  CAS  Google Scholar 

  38. Muls E., Blaton M., Rosseneu M., Lesaffre E., Lamerights G., De Moor P. Serum lipids and apolipoproteins A-I, AII, and B in hyperthyroidism before and after treatment. J. Clin. Endocrinol. Metab. 1982, 55: 459–464.

    Article  PubMed  CAS  Google Scholar 

  39. Boberg J., Dahlberg P.A., Vessby B., Lithell H. Serum lipoprotein and apolipoprotein concentrations in patients with hyperthyroidism and the effect of treatment with carbimazole. Acta Med. Scand. 1984, 215: 453–459.

    Article  PubMed  CAS  Google Scholar 

  40. Bonanome A., Pagnan A., Biffanti S., et al. Effect of dietary monounsaturated and polyunsaturated fatty acids on the susceptibility of plasma low density lipoproteins to oxidative modification. Arterioscler. Thromb. 1992, 12: 529–533.

    Article  PubMed  CAS  Google Scholar 

  41. La Du B.N. Human serum paraoxonase/arylesterase. In: Kalow W. editor. Pharmacogenetics of drug metabolism. Pergamon Press Inc., New York, 1992, p.51–91.

    Google Scholar 

  42. Mackness M.I., Mackness B., Durrington P.N., Connelly P.W., Hegele R.A. Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr. Opin. Lipidol. 1996, 7: 69–76.

    Article  PubMed  CAS  Google Scholar 

  43. Watson A.D., Berliner J.A., Hama S.Y., et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized lowdensity lipoprotein. J. Clin. Invest. 1995, 96: 2882–2891.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  44. McElveen J., Mackness M.I., Colley C.M., Peard T., Warner S., Walker C.H. Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. Clin. Chem. 1986, 32: 671–673.

    PubMed  CAS  Google Scholar 

  45. Fernandez V., Barrientos X., Kipreos K., Valenzuela A., Videla L.A. Superoxide radical generation, NADPH oxidase activity, and cytochrome P-450 content of rat liver microsomal fractions in an experimental hyperthyroid state: relation to lipid peroxidation. Endocrinology 1985, 117: 496–501.

    Article  PubMed  CAS  Google Scholar 

  46. Kleinveld H.A., Naber A.H., Stalenhoef A.F., Demacker P.N. Oxidation resistance, oxidation rate, and extent of oxidation of human low-density lipoprotein depend on the ratio of oleic acid content to linoleic acid content: studies in vitamin E deficient subjects. Free Radic. Biol. Med. 1993, 15: 273–280.

    Article  PubMed  CAS  Google Scholar 

  47. Shih D.M., Gu L., Hama S., et al. Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model. J. Clin. Invest. 1996, 97: 1630–1639.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  48. Navab M., Hama-Levy S., Van Lenten B.J., et al. Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. J. Clin. Invest. 1997, 99: 2005–2019.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  49. Mackness M.I., Durrington P.N., Mackness B. How highdensity lipoprotein protects against the effects of lipid peroxidation. Curr. Opin. Lipidol. 2000, 11: 383–388.

    Article  PubMed  CAS  Google Scholar 

  50. Nishio E., Watanabe Y. Cigarette smoke extract inhibits plasma paraoxonase activity by modification of the enzyme’s free thiols. Biochem. Biophys. Res. Commun. 1997, 236: 289–293.

    Article  PubMed  CAS  Google Scholar 

  51. Sen-Banerjee S., Siles X., Campos H. Tobacco smoking modifies association between Gln-Arg192 polymorphism of human paraoxonase gene and risk of myocardial infarction. Arterioscler. Thromb. Vasc. Biol. 2000, 20: 2120–2126.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Endocrine Research Center, Shaheed Beheshti University of Medical Sciences, P.O. Box 4763, Tehran, 19395, I.R. Iran

    F. Azizi MD, F. Raiszadeh, M. Solati, A. Etemadi, M. Rahmani & M. Arabi

Authors
  1. F. Azizi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Raiszadeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Solati
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Etemadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Rahmani
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. Arabi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to F. Azizi MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Azizi, F., Raiszadeh, F., Solati, M. et al. Serum paraoxonase 1 activity is decreased in thyroid dysfunction. J Endocrinol Invest 26, 703–709 (2003). https://doi.org/10.1007/BF03347350

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03347350

Key-words

Search

Navigation